NewLimit (@newlimit) — Twitter Score 173 out of 1000

NewLimit is a longevity biotech company working to extend human healthspan by restoring youthful function in aging cells through epigenetic reprogramming. NewLimit's Twitter Score is 173 out of 1000 (an Excellent rating) as of August 2026, ranking #2,971 (top 1%) among 483,944 tracked accounts.

NewLimit was co-founded by Jacob Kimmel, Brian Armstrong, and Blake Byers, with its mission centered on inventing medicines that add healthy years to human life. The company initially raised $105 million from its co-founders in 2021, followed by a $40 million Series A in May 2023. In June 2026, NewLimit completed a further funding round that valued the company at $3.1 billion, with $435 million invested in total at that point.

NewLimit counts among its backers Founders Fund, Thrive Capital, Greenoaks, Kleiner Perkins, Quiet Capital, Eli Lilly's venture arm, Valor Equity Partners, S32, Duke University Management Company, Liberty Mutual Investments, and individual investors including Fred Ehrsam, Elad Gil, Joe Lonsdale, Eric Schmidt, and Garry Tan. As of June 2026, NewLimit's first drug candidate, targeting alcohol-related liver disease, was expected to begin human studies within the following year.

NewLimit has published 107 posts on the platform and has been mentioned by 56 accounts a total of 94 times.

Who follows NewLimit on X?

The accounts that follow NewLimit include 805 founders, 231 angel investors, 228 influencers and 13 VCs, among them Chris Dixon, Brian Armstrong, Erik Voorhees, Stani, Mert and Fred Ehrsam.